SIGNAL DETECTION USING DATA FROM FDA ADVERSE EVENT REPORTING SYSTEM (FAERS): INFECTIONS IN BIOLOGICS VS BIOSIMILARS

被引：0
|
作者：
Patel, U. [1 ]
Eguale, T. [1 ]
Rittenhouse, B. [2 ]
Yunusa, I [3 ]
Kandikatla, R. [4 ]
Fathima, A. [5 ]
机构：
[1] MCPHS Univ, Boston, MA USA
[2] MCPHS Univ, Winchester, MA USA
[3] Univ South Carolina, Columbia, SC 29208 USA
[4] MCPHS Univ, Malden, MA USA
[5] MCPHS Univ, Roxbury, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH146
引用
收藏
页码：S191 / S191
页数：1
相关论文
共 50 条
  • [21] Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS)
    Zhan, Ruijia
    Lin, Jiageng
    Dai, Miao
    Ji, Bo
    He, Xianxia
    Jiang, Zhihui
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [22] Atezolizumab and severe cutaneous adverse reactions: a disproportionality analysis using FDA Adverse Event Reporting System (FAERS)
    Pecere, Alessandro
    Bisinella, Giulia Carlotta
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 35 - 35
  • [23] A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
    Liu, Liyuan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
    Wichelmann, Thomas A.
    Abdulmujeeb, Sufyan
    Ehrenpreis, Eli D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (10) : 1290 - 1297
  • [25] Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
    Zhang, Weidong
    Chen, Yunzhou
    Yao, Zeyu
    Ouyang, Mengling
    Sun, Minghui
    Zou, Shupeng
    PHARMACEUTICALS, 2025, 18 (01)
  • [26] A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database
    Yang, Haiyan
    Wan, Zheng
    Chen, Moliang
    Zhang, Xiaohong
    Cui, Wugeng
    Zhao, Bin
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (04) : 217 - 223
  • [27] Time to onset analysis of montelukast associated suicidal ideation using data from FDA adverse event reporting system database (FAERS)
    Viswam, Subeesh Kulangara
    Reddy, Neha
    Yalamanchili, Jahnavi
    Dsouza, Prizvan Lawrence
    Mazhar, Faizan
    Gouri, Nair
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 479 - 479
  • [28] DISPROPORTIONALITYANALYSIS WITH COMPARISON OF ELAGOLIX VERSUS LEUPROLIDE SAFETY IN WOMEN WITH ENDOMETRIOSIS USING DATA FROM THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)
    Gornet, Megan E.
    Bedrick, Bronwyn S.
    Cameron, Katherine E.
    FERTILITY AND STERILITY, 2024, 122 (04) : E82 - E83
  • [29] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    BMC Pharmacology and Toxicology, 24
  • [30] EXISTENCE OF NOTORIETY BIAS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE AND ITS IMPACT ON SIGNAL STRENGTH
    Reddy, Ravindra N.
    Viswam, K. S.
    Thomas, B. E.
    Nair, G.
    Maheswari, E.
    Swaroop, A. M.
    VALUE IN HEALTH, 2019, 22 : S763 - S763
12345